thiotepa has been researched along with Ewing Sarcoma in 14 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a patient with renal insufficiency (creatinine clearance, CL(cr) = 38 mL/min) who received high-dose chemotherapy with cyclophosphamide (1,500 mg/m(2) day(-1)), thiotepa (120 mg/m(2) day(-1)) and carboplatin (AUC = 5 mg min/mL day(-1)) for four consecutive days." | 7.75 | Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency. ( Beijnen, JH; Ekhart, C; Huitema, AD; Kerst, JM; Rodenhuis, S, 2009) |
| "We report a patient with renal insufficiency (creatinine clearance, CL(cr) = 38 mL/min) who received high-dose chemotherapy with cyclophosphamide (1,500 mg/m(2) day(-1)), thiotepa (120 mg/m(2) day(-1)) and carboplatin (AUC = 5 mg min/mL day(-1)) for four consecutive days." | 3.75 | Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency. ( Beijnen, JH; Ekhart, C; Huitema, AD; Kerst, JM; Rodenhuis, S, 2009) |
| " Whenever one patient at one dosage level showed a grade III or grade IV reversible toxicity, additional patients were admitted (one by one) up to a maximum number of 6." | 2.69 | Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors. ( Bella, S; Burnelli, R; Garaventa, A; Locatelli, F; Melchionda, F; Paolucci, G; Pession, A; Prete, A, 1999) |
| "ThioTEPA was administered intravenously every three weeks, at a dose of 65 mg/m2." | 2.68 | A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study. ( Balis, FM; Bleyer, WA; Broxson, E; Geyer, JR; Heideman, R; Krailo, MD; Poplack, D; Sato, JK, 1996) |
| "Melphalan was given i." | 2.68 | High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors. ( Ater, J; Chan, KW; Choroszy, M; Herzog, C; Jaffe, N; Korbling, M; Petropoulos, D, 1997) |
| "Primary Ewing's sarcoma of the spine is reviewed, and seven cases are presented." | 2.38 | Treatment options in primary Ewing's sarcoma of the spine: report of seven cases and review of the literature. ( el-Khoury, GY; Haddad, FS; Haddad, SF; Hitchon, PW; Sharafuddin, MJ, 1992) |
| " The conditioning regimen was well tolerated, without any toxic deaths." | 1.36 | Toxicity of high-dose chemotherapy with etoposide, thiotepa and CY in treating poor-prognosis Ewing's sarcoma family tumors: the experience of the Bambino Gesù Children's Hospital. ( Cozza, R; De Ioris, MA; De Lurentis, C; De Sio, L; Fidani, P; Ilari, I; Jenkner, A; Milano, GM; Pessolano, R, 2010) |
| "All compounds reduced the growth of Ewing tumor cell lines in a dose-dependent manner." | 1.33 | In-vitro toxicity of Ukrain against human Ewing tumor cell lines. ( Boos, J; Köster, J; Lanvers-Kaminsky, C; Nolting, DM; Sandkötter, J; Schröder, A, 2006) |
| "The principles of dose-response and combination chemotherapy were basic to the design of the initial curative standard-dose treatment regimens for leukemias, lymphomas, and testis cancer." | 1.28 | A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. ( Burke, J; Eder, JP; Elias, A; Frei, E; Hunt, M; Schnipper, LE; Schryber, SM; Shea, TC; Siegel, R; Teicher, BA, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 6 (42.86) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Loschi, S | 1 |
| Dufour, C | 1 |
| Oberlin, O | 1 |
| Goma, G | 1 |
| Valteau-Couanet, D | 1 |
| Gaspar, N | 1 |
| Jahnukainen, K | 1 |
| Kallio, P | 1 |
| Koivusalo, A | 1 |
| Saarinen-Pihkala, UM | 1 |
| Ilari, I | 1 |
| De Ioris, MA | 1 |
| Milano, GM | 1 |
| Pessolano, R | 1 |
| De Lurentis, C | 1 |
| De Sio, L | 1 |
| Fidani, P | 1 |
| Jenkner, A | 1 |
| Cozza, R | 1 |
| Lanvers-Kaminsky, C | 1 |
| Nolting, DM | 1 |
| Köster, J | 1 |
| Schröder, A | 1 |
| Sandkötter, J | 1 |
| Boos, J | 1 |
| Ekhart, C | 1 |
| Kerst, JM | 1 |
| Rodenhuis, S | 1 |
| Beijnen, JH | 1 |
| Huitema, AD | 1 |
| Geyer, JR | 1 |
| Balis, FM | 1 |
| Krailo, MD | 1 |
| Heideman, R | 1 |
| Broxson, E | 1 |
| Sato, JK | 1 |
| Poplack, D | 1 |
| Bleyer, WA | 1 |
| Chan, KW | 1 |
| Petropoulos, D | 1 |
| Choroszy, M | 1 |
| Herzog, C | 1 |
| Jaffe, N | 1 |
| Ater, J | 1 |
| Korbling, M | 1 |
| Yonemoto, T | 1 |
| Tatezaki, S | 1 |
| Ishii, T | 1 |
| Satoh, T | 1 |
| Pession, A | 1 |
| Prete, A | 1 |
| Locatelli, F | 1 |
| Bella, S | 1 |
| Melchionda, F | 1 |
| Garaventa, A | 1 |
| Burnelli, R | 1 |
| Paolucci, G | 1 |
| Hawkins, D | 1 |
| Barnett, T | 1 |
| Bensinger, W | 1 |
| Gooley, T | 1 |
| Sanders, J | 1 |
| Kushner, BH | 1 |
| Meyers, PA | 1 |
| Sharafuddin, MJ | 1 |
| Haddad, FS | 1 |
| Hitchon, PW | 1 |
| Haddad, SF | 1 |
| el-Khoury, GY | 1 |
| Eder, JP | 1 |
| Elias, A | 1 |
| Shea, TC | 1 |
| Schryber, SM | 1 |
| Teicher, BA | 1 |
| Hunt, M | 1 |
| Burke, J | 1 |
| Siegel, R | 1 |
| Schnipper, LE | 1 |
| Frei, E | 1 |
| Clément, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Trial of Busulfan, Thiotepa and Melphalan Followed by Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation and Followed by Total Marrow (Skeletal) Irradiation (TMI) in Patients With High-Risk Ewing's Sarcoma, PNET or Rhabdomyosarco[NCT00003081] | Phase 1 | 16 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients[NCT03542097] | 82 participants (Actual) | Observational | 2014-04-15 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thiotepa and Ewing Sarcoma
| Article | Year |
|---|---|
How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neopl | 2001 |
Treatment options in primary Ewing's sarcoma of the spine: report of seven cases and review of the literature.
Topics: Adolescent; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cervical V | 1992 |
5 trials available for thiotepa and Ewing Sarcoma
| Article | Year |
|---|---|
Tandem high-dose chemotherapy strategy as first-line treatment of primary disseminated multifocal Ewing sarcomas in children, adolescents and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child; Child, | 2015 |
A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Humans; Neoplasms; Neuroectode | 1996 |
High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 1997 |
Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 1999 |
Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2000 |
7 other studies available for thiotepa and Ewing Sarcoma
| Article | Year |
|---|---|
High-dose Thiotepa as Consolidation Therapy With Autologous Hematopoietic Stem Cell Transplantation for High-risk Ewing Family Tumors: Single-institution Experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone | 2015 |
Toxicity of high-dose chemotherapy with etoposide, thiotepa and CY in treating poor-prognosis Ewing's sarcoma family tumors: the experience of the Bambino Gesù Children's Hospital.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Chil | 2010 |
In-vitro toxicity of Ukrain against human Ewing tumor cell lines.
Topics: Berberine Alkaloids; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chelidonium; Dose-Response | 2006 |
Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Drug Interacti | 2009 |
[High-dose chemotherapy with autologous peripheral blood stem cell transplantation (PBSCT) for refractory bone and soft tissue sarcomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; | 1999 |
A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1990 |
[The chemotherapy of cancer].
Topics: Adult; Alkylating Agents; Antimetabolites; Antineoplastic Agents; Dactinomycin; Female; Fluorouracil | 1967 |